World Journal of Analytical Chemistry
ISSN (Print): 2333-1178 ISSN (Online): 2333-1283 Website: http://www.sciepub.com/journal/wjac Editor-in-chief: Raluca-Ioana Stefan-van Staden
Open Access
Journal Browser
Go
World Journal of Analytical Chemistry. 2013, 1(3), 31-36
DOI: 10.12691/wjac-1-3-2
Open AccessArticle

Stability Indicating HPTLC Determination of Terazosin in Tablet Formulation

Alankar SHRIVASTAVA1, , Abhishek PATEL1 and Vipin B. GUPTA2

1Department of Pharmaceutical Analysis, B.R. Nahata College of Pharmacy, Mandsaur, Madhya Pradesh, India

2B.R. Nahata College of Pharmacy, Mandsaur, Madhya Pradesh, India

Pub. Date: June 20, 2013

Cite this paper:
Alankar SHRIVASTAVA, Abhishek PATEL and Vipin B. GUPTA. Stability Indicating HPTLC Determination of Terazosin in Tablet Formulation. World Journal of Analytical Chemistry. 2013; 1(3):31-36. doi: 10.12691/wjac-1-3-2

Abstract

A simple, rapid and precise HPTLC method was developed for the quantitative estimation of terazosin hydrochloride in pharmaceutical dosage form. Good sharp peak was obtained in mobile phase composition Chloroform:Toluene:MeOH (9:1:6) at Rf ≈ 8. Stationary phase was silica gel precoated aluminum plate 60F-254 plates, [20cm × 10cm with 250μm thickness and wavelength selected was 254nm. Terazosin was exposed to acidic, alkaline, thermal, photolytic and oxidative stress conditions, and the stressed samples were analyzed by the proposed method. The described method showed linearity over a range of 50-2500μg/ml. The correlation coefficient is 0.999. Overall, the proposed method was found to be suitable and accurate for quantitative determination and stability study of terazosin in pharmaceutical dosage form.

Keywords:
terazosin hydrochloride stability indicating method stress degradation validation of analytical method

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 8

References:

[1]  Nageswari A, Krishna reddy KVSR, Mukkanti K, “Stability-indicating UPLC method for determination of Imatinib Mesylate and their degradation products in active pharmaceutical ingredient and Pharmaceutical dosage forms.” J Pharma Biomed Anal, 66, 109-115, 2012.
 
[2]  Makhija SN, Vavia PR, “Stability indicating LC method for the estimation of venlafaxine in pharmaceutical formulations.” J Pharma Biomed Anal, 28, 1055-1059, 2002.
 
[3]  Bakshi M, Singh S, “Development of validated stability-indicating assay methods-critical review.” J Pharma Biomed Anal, 28, 1011-1040, 2002.
 
[4]  Ahirrao VK, Patil CS, Bembalkar SB, Ubale SB, Marathe RP, Nawale RB, Landge MG, Pawar RP, “Stability-Indicating LC Method for the Determination of Prasugrel Hydrochloride in Pharmaceutical Dosage Form.” Sci Pharm, 80, 379-391, 2012.
 
[5]  Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW, “PPARγ: A molecular link between systemic metabolic disease and benign prostate hyperplasia.” Differentiation 82, 220-236, 2011.
 
[6]  Shrivastava A, Gupta VB, “Various treatment options for benign prostatic hyperplasia: A current update.” J Mid-life health, 3(1), 10-19, 2012.
 
[7]  Shrivastava A, Saxena P, Gupta VB, “Spectrophotometric estimation of tamsulosin hydrochloride by acid-dye method.” Pharm Methods 2, 53-60, 2011.
 
[8]  Perabo FGE, “Drug development for LUTS - The challenge for industry.” Drug Discov Today: Ther Strategies, Corrected proof, 2012.
 
[9]  European Pharmacopoeia, European Directorate for the Quality of Medicines. Strasbourg, p. 2318, 1911, 2007.
 
[10]  Shrivastava A, Gupta VB, “A Review on Various Analytical Methods on Some Alpha Adrenergic Antagonists.” Curr Pharm Anal, 7, 27-41, 2011.
 
[11]  Lepor H, Laddu A, “Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.” Br J Urol, 70, Suppl 1, 2-9, 1992.
 
[12]  Attimarad M, Mueen Ahmed KK, Aldhubaib BE, Harsha S, “High-performance thin layer chromatography: A powerful analytical technique in pharmaceutical drug discovery.” Pharm Methods, 2, 71-5, 2011.
 
[13]  Shrivastava A, Gupta VB, “HPLC: Isocratic or Gradient Elution and Assessment of Linearity in Analytical Methods.” J Adv Scient Res, 3(2), 12-20, 2012.
 
[14]  Sankar V, Raghuraman S, Sivanand V, Ravichandran V, “Spectrophotometric method for the estimation of Terazosin in Tablets.” Ind J Pharm Sci, 61(6), 463-464, 2000.
 
[15]  Prasad CVN, Gautham A, Bhardwaj V, Praimoo P, “Quantitative determination of Terazosin HCl in tablet preparation by fluorimetry.” Ind J Pharm Sci, 60(3), 167-9, 1998.
 
[16]  Zeeb M, Sadeghi M, “Sensitive Determination of Terazosin in Pharmaceutical Formulations and Biological Samples by Ionic-Liquid Microextraction Prior to Spectrofluorimetry.” Inter J Anal Chem, 1-7, 2012.
 
[17]  Zou HY, Wu HL, OuYang LQ, Zhang Y, Nie JF, Fu HY, Yu RQ, “Fluorescent quantification of terazosin hydrochloride content in human plasma and tablets using second-order calibration based on both parallel factor analysis and alternating penalty trilinear decomposition.” Analy Chim Acta, 650, 143-149, 2009.
 
[18]  Sekhar EC, Rao TRK, Sekhar KR, Naidu MUR, Shobha JC, Rani PU et al, “Determination of terazosin in human plasma using high performance liquid chromatography with fluorescence detection.” J Chromatogr B, 710, 137-142, 1998.
 
[19]  Taguchi K, Scha¨fers RF, Michel MC, “Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.” Br J Clin Pharmacol, 45, 49-55, 1998.
 
[20]  Zavitsanos AP, Alebic-Kolbah T. “Enantioselective determination of terazosin in human plasma by normal phase high-performance liquid chromatography-electrospray mass spectrometry.” J Chromatogr A, 794, 45-56, 1998.
 
[21]  Cheah PY, Yuena KH, Liong ML, “Improved high performance liquid chromatographic analysis of terazosin in human plasma.” J Chromatogr B, 745, 439-443, 2000.
 
[22]  Chang Zui L, Bauer JF, “Analytical Profile of Drug Substances.” 20th volume, Academic Press, Elsevier, 717-720, 2005.
 
[23]  Shrivastava A, Gupta VB, “Validated HPLC and HPTLC Methods for Simultaneous Determination of Some α1-Adrenoreceptor Blockers.” Lat Amer J Pharm, 31 (2), 279-86, 2012.
 
[24]  Shrivastava A, Gupta VB, “Simultaneous Determination of Two Alpha-One Adrenoreceptor Blockers Terazosin and Prazosin Using Tamsulosin as Internal Standard.” Inter J Pharm Pharma Sci, 4(3), 752-756, 2012.
 
[25]  Shrivastava A, Gupta VB, “Stability indicating RP-HPLC Method for Simultaneous Determination of Prazosin, Terazosin and Doxazosin in Pharmaceutical Formulations.” Sci Pharm 2012; 80: 619-31.
 
[26]  Bakshi M, Ojha T, Singh S, “Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions.” J Pharm Biomed Anal, 34, 19-2, 2004.
 
[27]  Shrivastava A, Gupta VB, “Ultra violet spectrophotometric method: Not possible for the simultaneous estimation of alpha one adrenoreceptor blockers.” J Pharm Negative Results, 2, 115-120, 2011.
 
[28]  Shrivastava A, Gupta VB, “Methods for the determination of limit of detection and limit of quantitation of the analytical methods.” Chron Young Sci, 2, 21-5, 2011.
 
[29]  Shrivastava A, “Analytical Methods for Venlaflaxine Hydrochloride and Metabolites Determinations in Different Matrices.” Syst Rev Pharm, 3, 42-50, 2012.